Role of preoperative chemotherapy for non-small-cell lung cancer: A meta-analysis

Lung Cancer

Volumn 54, Issue 3, 2006, Pages 325-329

  Nakamura, Haruhiko ^a   Kawasaki, Norihito ^a   Taguchi, Masahiko ^a   Kabasawa, Kazuyuki ^b  

^a International University of Health and Welfare   (Japan)

^b DAITO BUNKA UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Induction; Lung cancer; Meta analysis; Neoadjuvant; Preoperative; Surgery

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IFOSFAMIDE; MITOMYCIN; VINDESINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HAZARD ASSESSMENT; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDLINE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SURVIVAL TIME; TIME SERIES ANALYSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33750367545     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.07.019     Document Type: Article

References (31)

1. Spiro S., and Silvestri G. One hundred years of lung cancer. Am J Respir Crit Care Med 172 (2005) 523-529
2. Belani C. Adjuvant and neoadjuvant therapy in non-small cell lung cancer. Semin Oncol 32 (2005) S9-S15
3. Casali C., Stefani A., Natali P., Rossi G., and Morandi U. Prognostic factors in surgically resected N2 non-small cell lung cancer: the importance of patterns of mediastinal lymph nodes metastases. Eur J Cardiothorac Surg 28 (2005) 33-38
4. De C.M., Ashiku S., and Thurer R. The role of surgery in N2 non-small cell lung cancer. Clin Cancer Res 11 (2005) 5033s-5037s
5. Kato H., Ichinose Y., Ohta M., Hata E., Tsubota N., Tada H., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350 (2004) 1713-1721
6. Arriagada R., Bergman B., Dunant A., Le C.T., Pignon J., and Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
7. Mountain C. Revisions in the international system for staging lung cancer. Chest 111 (1997) 1710-1717
8. Pass H., Pogrebniak H., Steinberg S., Mulshine J., and Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg 53 (1992) 992-998
9. Roth J., Fossella F., Komaki R., Ryan M., Putnam J., Lee J., et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86 (1994) 673-680
10. Roth J., Atkinson E., Fossella F., Komaki R., Bernadette R.M., Putnam J.J., et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 21 (1998) 1-6
11. Rosell R., Gomez-Codina J., Camps C., Maestre J., Padille J., Canto A., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330 (1994) 153-158
12. Rosell R., Gomez-Codina J., Camps C., Javier S.J., Maestre J., Padilla J., et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 26 (1999) 7-14
13. Depierre A., Milleron B., Moro-Sibilot D., Chevret S., Quoix E., Lebeau B., et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 20 (2002) 247-253
14. Nagai K., Tsuchiya R., Mori T., Tada H., Ichinose Y., Koike T., et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg 125 (2003) 254-260
15. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
16. Mitsudomi T., Hamajima N., Ogawa M., and Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 6 (2000) 4055-4063
17. Egger M., Smith G., and Schneider M. Bias in meta-analysis detected by a simple, graphical test. Br Med J 315 (1997) 629-634
18. Andre F., Grunenwald D., Pignon J., Dujon A., Pujol J., Brichon P., et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 18 (2000) 2981-2989
19. Boer R., Smith I., Pastorino U., O'Brien M., Ramage F., Ashley S., et al. Preoperative chemotherapy in early stage resectable non-small-cell lung cancer: a randomized feasibility study justifying a multicentre phase III trial. Br J Cancer 79 (1999) 1514-1518
20. Martin J., Ginsberg R., Abolhoda A., Bains M., Downey R., Korst R., et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg 72 (2001) 1149-1154
21. Siegenthaler M., Pisters K., Merriman K., Roth J., Swisher S., Walsh G., et al. Preoperative chemotherapy for lung cancer does not increase surgical morbidity. Ann Thorac Surg 71 (2001) 1105-1111 [discussion 1111-2]
22. Mattson K., Abratt R., ten Velde G., and Krofta K. Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study. Ann Oncol 14 (2003) 116-122
23. Van S.P., Van M.J., Kramer G., Splinter T., Legrand C., Giaccone G., et al. Morbidity and mortality in the surgery arm of EORTC 08941 trial. Eur Respir J 26 (2005) 192-197
24. Yusuf S., Peto R., Lewis J., Collins R., and Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27 (1985) 335-371
25. Davey S.G., and Egger M. Meta-analyses of randomised controlled trials. Lancet 350 (1997) 1182
26. Stewart L., and Parmar M. Meta-analysis of the literature or of individual patient data: is there a difference?. Lancet 341 (1993) 418-422
27. Bunn P. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy. Clin Lung Cancer 6 (2004) 85-98
28. Berghmans T., Paesmans M., Meert A., Mascaux C., Lothaire P., Lafitte J., et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 49 (2005) 13-23
29. Johnstone D., Byhardt R., Ettinger D., and Scott C. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 54 (2002) 365-369
30. Shepherd F., Johnston M., Payne D., Burkes R., Deslauriers J., Cormier Y., et al. Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer: a National Cancer Institute of Canada Clinical Trials Group Study. Br J Cancer 78 (1998) 683-685
31. de Pas T., Pastorino U., Spaggiari L., Curigliano G., de Braud F., and Robertson C. Preoperative chemotherapy in non-small-cell lung cancer: nothing new in N2 disease. J Clin Oncol 20 (2002) 2603-2604